Literature DB >> 27264184

FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair.

Zeina Kais1, Beatrice Rondinelli1, Amie Holmes1, Colin O'Leary1, David Kozono1, Alan D D'Andrea2, Raphael Ceccaldi3.   

Abstract

BRCA1/2 proteins function in homologous recombination (HR)-mediated DNA repair and cooperate with Fanconi anemia (FA) proteins to maintain genomic integrity through replication fork stabilization. Loss of BRCA1/2 proteins results in DNA repair deficiency and replicative stress, leading to genomic instability and enhanced sensitivity to DNA-damaging agents. Recent studies have shown that BRCA1/2-deficient tumors upregulate Polθ-mediated alternative end-joining (alt-EJ) repair as a survival mechanism. Whether other mechanisms maintain genomic integrity upon loss of BRCA1/2 proteins is currently unknown. Here we show that BRCA1/2-deficient tumors also upregulate FANCD2 activity. FANCD2 is required for fork protection and fork restart in BRCA1/2-deficient tumors. Moreover, FANCD2 promotes Polθ recruitment at sites of damage and alt-EJ repair. Finally, loss of FANCD2 in BRCA1/2-deficient tumors enhances cell death. These results reveal a synthetic lethal relationship between FANCD2 and BRCA1/2, and they identify FANCD2 as a central player orchestrating DNA repair pathway choice at the replication fork.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27264184      PMCID: PMC4939765          DOI: 10.1016/j.celrep.2016.05.031

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  77 in total

1.  The importance of repairing stalled replication forks.

Authors:  M M Cox; M F Goodman; K N Kreuzer; D J Sherratt; S J Sandler; K J Marians
Journal:  Nature       Date:  2000-03-02       Impact factor: 49.962

2.  The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway.

Authors:  Sebastian M B Nijman; Tony T Huang; Annette M G Dirac; Thijn R Brummelkamp; Ron M Kerkhoven; Alan D D'Andrea; René Bernards
Journal:  Mol Cell       Date:  2005-02-04       Impact factor: 17.970

Review 3.  Causes and consequences of replication stress.

Authors:  Michelle K Zeman; Karlene A Cimprich
Journal:  Nat Cell Biol       Date:  2014-01       Impact factor: 28.824

Review 4.  DNA double-strand break repair pathway choice and cancer.

Authors:  Tomas Aparicio; Richard Baer; Jean Gautier
Journal:  DNA Repair (Amst)       Date:  2014-04-18

Review 5.  Mechanisms of resistance to therapies targeting BRCA-mutant cancers.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Nat Med       Date:  2013-10-07       Impact factor: 53.440

6.  Replicon clusters are stable units of chromosome structure: evidence that nuclear organization contributes to the efficient activation and propagation of S phase in human cells.

Authors:  D A Jackson; A Pombo
Journal:  J Cell Biol       Date:  1998-03-23       Impact factor: 10.539

7.  Mechanism of microhomology-mediated end-joining promoted by human DNA polymerase θ.

Authors:  Tatiana Kent; Gurushankar Chandramouly; Shane Michael McDevitt; Ahmet Y Ozdemir; Richard T Pomerantz
Journal:  Nat Struct Mol Biol       Date:  2015-02-02       Impact factor: 15.369

8.  BRCA1 haploinsufficiency for replication stress suppression in primary cells.

Authors:  Shailja Pathania; Sangeeta Bade; Morwenna Le Guillou; Karly Burke; Rachel Reed; Christian Bowman-Colin; Ying Su; David T Ting; Kornelia Polyak; Andrea L Richardson; Jean Feunteun; Judy E Garber; David M Livingston
Journal:  Nat Commun       Date:  2014-11-17       Impact factor: 14.919

9.  DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining.

Authors:  Sean M Howard; Diana A Yanez; Jeremy M Stark
Journal:  PLoS Genet       Date:  2015-01-28       Impact factor: 5.917

10.  Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair.

Authors:  Agata Smogorzewska; Shuhei Matsuoka; Patrizia Vinciguerra; E Robert McDonald; Kristen E Hurov; Ji Luo; Bryan A Ballif; Steven P Gygi; Kay Hofmann; Alan D D'Andrea; Stephen J Elledge
Journal:  Cell       Date:  2007-04-05       Impact factor: 41.582

View more
  68 in total

Review 1.  A tough row to hoe: when replication forks encounter DNA damage.

Authors:  Darshil R Patel; Robert S Weiss
Journal:  Biochem Soc Trans       Date:  2018-12-04       Impact factor: 5.407

2.  USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors.

Authors:  Kah Suan Lim; Heng Li; Emma A Roberts; Emily F Gaudiano; Connor Clairmont; Larissa Alina Sambel; Karthikeyan Ponnienselvan; Jessica C Liu; Chunyu Yang; David Kozono; Kalindi Parmar; Timur Yusufzai; Ning Zheng; Alan D D'Andrea
Journal:  Mol Cell       Date:  2018-12-20       Impact factor: 17.970

Review 3.  The impact of replication stress on replication dynamics and DNA damage in vertebrate cells.

Authors:  Hervé Técher; Stéphane Koundrioukoff; Alain Nicolas; Michelle Debatisse
Journal:  Nat Rev Genet       Date:  2017-07-17       Impact factor: 53.242

4.  Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing.

Authors:  Guoli Li; Xinwu Guo; Lili Tang; Ming Chen; Xipeng Luo; Limin Peng; Xunxun Xu; Shouman Wang; Zhi Xiao; Wenjun Yi; Lizhong Dai; Jun Wang
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-29       Impact factor: 4.553

5.  Wolf-Hirschhorn Syndrome Candidate 1 Is Necessary for Correct Hematopoietic and B Cell Development.

Authors:  Elena Campos-Sanchez; Nerea Deleyto-Seldas; Veronica Dominguez; Enrique Carrillo-de-Santa-Pau; Kiyoe Ura; Pedro P Rocha; JungHyun Kim; Arafat Aljoufi; Anna Esteve-Codina; Marc Dabad; Marta Gut; Holger Heyn; Yasufumi Kaneda; Keisuke Nimura; Jane A Skok; Maria Luisa Martinez-Frias; Cesar Cobaleda
Journal:  Cell Rep       Date:  2017-05-23       Impact factor: 9.423

6.  EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.

Authors:  Beatrice Rondinelli; Ewa Gogola; Hatice Yücel; Alexandra A Duarte; Marieke van de Ven; Roxanne van der Sluijs; Panagiotis A Konstantinopoulos; Jos Jonkers; Raphaël Ceccaldi; Sven Rottenberg; Alan D D'Andrea
Journal:  Nat Cell Biol       Date:  2017-10-16       Impact factor: 28.824

7.  DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.

Authors:  Rachel Abbotts; Michael J Topper; Christopher Biondi; Daniel Fontaine; Reena Goswami; Lora Stojanovic; Eun Yong Choi; Lena McLaughlin; Aksinija A Kogan; Limin Xia; Rena Lapidus; Javed Mahmood; Stephen B Baylin; Feyruz V Rassool
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-07       Impact factor: 11.205

8.  Sex-specific hepatic lipid and bile acid metabolism alterations in Fancd2-deficient mice following dietary challenge.

Authors:  Elizabeth S Moore; Erin K Daugherity; David I Karambizi; Bethany P Cummings; Erica Behling-Kelly; Deanna M W Schaefer; Teresa L Southard; Joseph W McFadden; Robert S Weiss
Journal:  J Biol Chem       Date:  2019-08-21       Impact factor: 5.157

Review 9.  Fanconi anaemia and cancer: an intricate relationship.

Authors:  Grzegorz Nalepa; D Wade Clapp
Journal:  Nat Rev Cancer       Date:  2018-01-29       Impact factor: 60.716

10.  A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

Authors:  Marta Castroviejo-Bermejo; Cristina Cruz; Alba Llop-Guevara; Sara Gutiérrez-Enríquez; Mandy Ducy; Yasir Hussein Ibrahim; Albert Gris-Oliver; Benedetta Pellegrino; Alejandra Bruna; Marta Guzmán; Olga Rodríguez; Judit Grueso; Sandra Bonache; Alejandro Moles-Fernández; Guillermo Villacampa; Cristina Viaplana; Patricia Gómez; Maria Vidal; Vicente Peg; Xavier Serres-Créixams; Graham Dellaire; Jacques Simard; Paolo Nuciforo; Isabel T Rubio; Rodrigo Dienstmann; J Carl Barrett; Carlos Caldas; José Baselga; Cristina Saura; Javier Cortés; Olivier Déas; Jos Jonkers; Jean-Yves Masson; Stefano Cairo; Jean-Gabriel Judde; Mark J O'Connor; Orland Díez; Judith Balmaña; Violeta Serra
Journal:  EMBO Mol Med       Date:  2018-12       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.